Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease

NCT03687476 is registered in ClinicalTrials.gov with Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company as lead sponsor.

NCT NCT03687476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03687476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease
Lead sponsor
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2020
Completion date
October 30, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

niemann-pick disease, type c